SEC Tracker
Get the app

BioAge Labs BIOA

BioAge Labs reports Q3 2026 financial results and clinical updates

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Collaboration revenue was $0.3 million for Q3 2026, down from $2.1 million in Q3 2025.
  2. QUELL-DME Phase 2 trial for BGE-102 enrolled 180 participants, with topline results expected in 2027.
  3. QUELL-CV Phase 2 trial for BGE-102 completed enrollment of 160 participants, with topline data expected in Q4 2026.
  4. BioAge plans to file its first IND for an APJ agonist program by end of 2026.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BioAge Labs files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Caribou Biosciences CRBU public float $113M, Jun 30, 2025
  2. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  3. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  4. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  5. TuHURA Biosciences HURA public float $111M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.